P110 heptapeptide

• UNSPSC Description:

  P110 heptapeptide, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1[1].

• Target Antigen:

  Dynamin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/p110.html

• Purity:

  99.84

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC(C[C@H](N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Weight:

  756.85

• References & Citations:

  [1]Luis Rios, et al. Targeting an allosteric site in dynamin-related protein 1 to inhibit Fis1-mediated mitochondrial dysfunction. Nat Commun. 2023 Jul 19;14(1):4356.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1411976-18-5